Cachexia
Active team: CANCAN
Challenge: Understand and reverse cachexia and declining performance status in cancer patients.
We set this challenge in 2020, which team CANCAN is currently tackling. We're not accepting new applications.
Please note that the description below reflects the challenge as set by our Scientific Committee in 2020; we understand that there may have been developments in the field between then and now.
If you're interested in a plain language summary of the challenge, you can find it at the bottom of the page.
Context
Many patients with advanced cancer suffer from a devastating syndrome termed cachexia. This is characterised by significant weight loss from both loss of skeletal muscle and fatty tissue that can’t be reversed by nutritional support. These symptoms are often accompanied by fatigue and a declining performance status that imparts a poor prognosis. Understanding the causal mechanism of this syndrome would open the door for the development of novel interventions, which could improve treatment response, quality of life, and survival.
Barriers and opportunities
Cachexia, fatigue, and poor performance status are common problems in patients with advanced cancer. Although there is a limited understanding of the molecular basis of these clinical phenomena, current research has suggested that these may be a result of a complex set of interactions between the tumour and the patient that includes release of inflammatory cytokines and tumour and host metabolic changes. Research has begun to uncover some cancer cell intrinsic mechanisms, but we know little about how tumours interact with the stroma and host in this setting. Pre-clinical and clinical studies have generated plausible mediators of cachexia, however, there has been little impact on patient benefit when such mediators are targeted in clinic.
This calls for bold new approaches to better understand and treat cachexia, fatigue and declining performance status. This might include:
- Generating a deeper molecular understanding of cachexia and fatigue
- Can preclinical models be developed that recapitulate these conditions?
- Can we identify methods to manipulate the pathways involved and identify treatment targets?
- Are there biomarkers predicting the onset of cancer cachexia? And once identified could these lead to the development of biomarker driven clinical trials to prevent or reverse its onset?
Vision and Impact
This challenge seeks to expand our mechanistic understanding of cachexia, fatigue, and poor performance status that severely impact the quality of life of cancer patients and limit our ability to deliver systemic therapies. Please note, although we recognise that many patients may have prolonged treatment-related fatigue, the focus of this challenge should be on addressing and reversing the causal mechanisms of cancer cachexia, declining performance status and fatigue independent of therapy.
It will require a multidisciplinary research team that could include expertise in metabolism, endocrinology, biology, immunology, neurohormonal biology, clinical oncology, chemistry and pharmacology.
Through this funding, it is hoped that new insights will be gained that can be translated into clinical interventions that will improve treatment outcomes and quality of life for patients with advanced cancer.
Plain language summary: Why cachexia?
In the late stages of cancer, people often undergo extreme weight-loss and muscle wasting – a condition called cachexia. These individuals’ general well-being can also degenerate in other ways – they become weak and tired, with even every-day activities becoming challenging.
We understand very little about what causes cachexia and eating more or receiving nutritional supplements doesn’t seem to help. Crucially, cancer treatments are less likely to be effective in people who have cachexia and other signs of deteriorating well-being.
To develop better ways to help people whose health deteriorates in this way, this Cancer Grand Challenge invites multidisciplinary teams to find bold new ways to unpick the complicated pathways involved. New treatments could vastly improve the quality of life and survival of people with late-stage cancer.